D44.7 Insurance Policy Changes

ICD-10 D44.7 is officially defined as "Neoplasm of uncertain behavior of aortic body and other paraganglia." code D44.7 is referenced in 3 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code D44.7 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Aug 16, 2026Medium impact
Irreversible Electroporation (NanoKnife) (CPB 0828, reviewed 2026-03-03)
This is an older Aetna clinical policy bulletin (CPB 0828) on irreversible electroporation (IRE), including the NanoKnife system for tissue ablation. It was last reviewed 03/03/2026, and its original effective date is 06/15/2012. Aetna considers IRE experimental, investigational or unproven for all indications, including the listed indications such as hepatocellular carcinoma, pancreatic cancer, prostate cancer, renal masses, lung nodules and breast cancer, because the peer-reviewed literature has insufficient evidence.
Aetna · Identified Aug 16, 2026Medium impact
Lutetium Lu 177 Dotatate (Lutathera) and Lutetium Lu 177 Vipivotide Tetraxetan (Pluvicto) (CPB 0929, reviewed 2026-07-17)
Aetna's policy covers lutetium Lu 177 dotatate (Lutathera) and lutetium Lu 177 vipivotide tetraxetan (Pluvicto) for commercial medical plans. Lutathera is medically necessary for four doses total for specified somatostatin receptor-positive neuroendocrine tumors, poorly controlled carcinoid syndrome, and pheochromocytoma/paraganglioma when the listed criteria are met, and Pluvicto is medically necessary for up to 6 total doses lifetime for PSMA-positive metastatic castration-resistant prostate cancer when all listed criteria are met. Aetna considers both drugs experimental, investigational, or unproven for all other indications, including Lutathera for medullary thyroid carcinoma and meningioma.
Aetna · Identified Aug 16, 2026Medium impact
RET Proto-Oncogene Testing (CPB 0319, reviewed 2026-06-08)
Aetna considers germline RET proto-oncogene testing medically necessary for members with a personal history of medullary thyroid carcinoma (familial or apparently sporadic), pheochromocytoma or paraganglioma when multiple endocrine neoplasia type 2 (MEN2) is suspected, parathyroid adenoma or hyperplasia when MEN2A is suspected, C-cell hyperplasia on pathology, or clinical features of MEN2B. Family history criteria include a first-degree blood relative with medullary thyroid carcinoma, a first-degree or second-degree blood relative with a known germline RET pathogenic variant, and a family pattern consistent with familial medullary thyroid carcinoma. Germline RET testing for all other indications, such as non-small cell lung cancer, is considered experimental, investigational, or unproven.

Watch D44.7

Get one email when a payer policy names D44.7, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code D44.7?

There are 3 tracked policy changes affecting code D44.7, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code D44.7?

Payers that have issued tracked updates for code D44.7 include: Aetna.

How do I get notified when code D44.7 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code D44.7. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code D44.7?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Irreversible Electroporation (NanoKnife) (CPB 0828, reviewed 2026-03-03)

Lutetium Lu 177 Dotatate (Lutathera) and Lutetium Lu 177 Vipivotide Tetraxetan (Pluvicto) (CPB 0929, reviewed 2026-07-17)

RET Proto-Oncogene Testing (CPB 0319, reviewed 2026-06-08)

What insurance policy changes affect code D44.7?

Which payers have updated policy for code D44.7?

How do I get notified when code D44.7 policy changes?

Why do payers change policies for code D44.7?